Sofgen Pharma S.A carried $41.4M in long-term debt against $30.3M in cash and equivalents at the end of fiscal year 2024. Long-term debt rose 33.1% from the prior fiscal year. The table below carries 6 fiscal years, from 2019 to 2024, and the quarters Sofgen Pharma S.A has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
PROCF Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
PROCF Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q4'2420-F | Q4'2320-F | Q2'236-K | Q4'2220-F | Q2'226-K | Q4'2120-F | Q4'2020-F | Q4'1920-F | Q4'1820-F |
|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $41.4M+33.1% | $31.1M+6.7% | $169.6M | $29.2M+0.4% | N/A | $29.0M-91.5% | $339.7M+6.0% | $320.5M+5.0% | $305.2M |
| Cash & Equivalents | $30.3M+73.1% | $17.5M-59.3% | $11.5M-69.3% | $43.0M-40.4% | $37.6M | $72.1M+1605.2% | $4.2M+107.1% | $2.0M-28.2% | $2.8M |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Sofgen Pharma S.A financials
Frequently Asked Questions
Sofgen Pharma S.A carried $41.4M in long-term debt against $30.3M in cash and equivalents at the end of fiscal year 2024.
Sofgen Pharma S.A (PROCF) long-term debt rose by 33.1% year over year, from $31.1M to $41.4M in fiscal year 2024.
Across the 6 fiscal years this page covers, Sofgen Pharma S.A (PROCF) long-term debt went from $320.5M in fiscal year 2019 to $41.4M in fiscal year 2024.
Sofgen Pharma S.A (PROCF) reported $41.4M in long-term debt in Q4 2024. This represents an increase of 33.1% from the same quarter a year earlier.
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Sofgen Pharma S.A (PROCF) reported on that line in every period on record.